Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 13 December 2025 - 17 December 2025

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

December 17, 2025 Pfizer Inc. (NYSE: PFE) stock is back in the spotlight on December 17 as investors digest the company’s newly issued full-year 2026 financial guidance, along with a stack of fresh reporting and analyst commentary about what comes next for one of the world’s biggest drugmakers. The immediate market reaction has been skeptical: Pfizer’s outlook points to another year of flat-to-down top-line performance as COVID-era revenue continues to normalize and a looming loss-of-exclusivity (LOE) cycle begins to bite harder. Pfizer+1 As of 00:43 UTC on Dec. 17 (late Dec. 16 in New York), Pfizer shares were about $25.53,
17 December 2025
·····
Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Inc. (NYSE: PFE) finished Tuesday’s session sharply lower after investors digested the company’s newly issued full‑year 2026 financial guidance—and the market’s message was clear: Wall Street wants more certainty on when Pfizer’s post‑COVID growth engine fully re-ignites. Pfizer stock price after the bell: where PFE stands tonight Pfizer shares closed at $25.53, down 3.41% on the day, then edged down in extended trading to about $25.45 as of early evening (5:21 p.m. ET). The stock traded in a wide range Tuesday, roughly $24.92 to $26.51, on heavy volume (about 110.9 million shares). StockAnalysis That “down hard, then mostly steady
16 December 2025
·····
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25. The market’s message was clear: Pfizer’s transition away from pandemic-era revenue is still a work in progress, and 2026 is shaping up as another “bridge year” where lower COVID-19 sales and patent expirations pressure results—partly
16 December 2025
·····
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and exclusivity headwinds. On December 16, 2025, Pfizer issued its full-year 2026 guidance, projecting revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00—both ranges that came in below Wall Street expectations cited by major financial outlets covering the update. Business Wire+2Reuters+2 The market reaction has been measured. After a strong move higher on Monday tied to
16 December 2025
····
Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. (NYSE: PFE) heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas (immunology and obesity), and a regulatory backdrop that can flip sentiment faster than a lab centrifuge. Shares closed Monday at $26.43, up 2.24%, extending a four-session winning streak, according to MarketWatch. MarketWatch On the data side, Pfizer’s own calendar is the center of gravity: the company is scheduled to host an 8:00 a.m. EST analyst call today to provide full-year 2026 financial guidance. Pfizer+1 Below is what’s driving
16 December 2025
·····
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer, Inc. (NYSE: PFE) is back in focus on Monday, December 15, 2025, with investors weighing fresh collaboration news, a looming guidance event, and a familiar debate: is Pfizer stock a high-yield value play with a rebuilding pipeline—or a “wait-and-see” story facing years of patent headwinds? As of Monday’s session, Pfizer stock is trading around $26.36. That places PFE near the upper end of its recent trading band and within reach of its 52-week high of $27.69 (52-week low $20.92), underscoring how tightly the stock has ranged as markets await clearer 2026 direction. MarketBeat+1 Below is a detailed, news-driven look
15 December 2025
·····
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. (NYSE: PFE) enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy designed to refill the revenue engine ahead of major patent cliffs. The immediate spotlight is tomorrow morning’s full-year 2026 guidance call—a scheduled catalyst that can reset expectations for revenue, margins, and capital allocation going into 2026. Pfizer Pfizer stock price today: where PFE stands on Dec. 15, 2025 As of 12:08 UTC on Monday, Pfizer shares traded at $25.85, essentially
15 December 2025
·····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer (NYSE: PFE) heads into Monday’s U.S. market open (Dec. 15, 2025) in a familiar spot for late 2025: investors are weighing a high dividend and aggressive deal-making against policy uncertainty for COVID vaccines and the company’s ongoing push to replace pandemic-era revenue with oncology and cardiometabolic growth. As of Friday’s close (Dec. 12), Pfizer shares finished around $25.85, near the middle-to-upper end of a $20.92–$27.69 52-week range. MarketWatch+1 The most immediate catalyst isn’t an earnings report—it’s Pfizer’s analyst call on Tuesday, Dec. 16 at 8:00 a.m. ET, where management is scheduled to provide full-year 2026 financial guidance. That call
14 December 2025
····
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Updated: Sunday, December 14, 2025 (U.S. markets last closed Friday, Dec. 12) Pfizer Inc. (NYSE: PFE) is ending the week in a familiar spot—trading in the mid‑$20s—while investors weigh a high dividend payout against a fast-moving set of catalysts: new oncology data from the Seagen portfolio, a fresh attempt at an oral obesity drug, ongoing cost-cutting, and a looming shift in the U.S. COVID vaccine policy backdrop. Reuters+3StockAnalysis+3Reuters+3 Below is a detailed roundup of the most important Pfizer stock headlines, forecasts, and analyst takes available as of Dec. 14, 2025, plus what to watch next heading into Pfizer’s scheduled 2026
14 December 2025
····
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Inc. (NYSE: PFE) heads into the new trading week with investors balancing two very different storylines: a steady, high-yield “value pharma” profile versus a news-driven catalyst tape around obesity deals, oncology data, cost cuts, and shifting U.S. COVID-vaccine policy. As of the latest close, Pfizer shares were around $25.85. With markets closed on Sunday (Dec. 14), the next big directional test arrives quickly: Pfizer’s analyst and investor call on Tuesday, Dec. 16, where management is scheduled to provide full-year 2026 financial guidance. Pfizer+1 Below is a detailed, news-driven look at what moved Pfizer stock in recent days—and what could
14 December 2025
·····
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: (1) the obesity-drug arms race, (2) Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and (3) a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3 The result is a “defensive sector” that doesn’t feel defensive at all right now. The Federal Reserve’s Dec. 9–10 meeting delivered another layer
14 December 2025
········
Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Updated Friday, Dec. 12, 2025. Pfizer (NYSE: PFE) heads into the final full trading week before the holidays with a familiar mix of catalysts: pipeline updates that support its post‑COVID growth narrative, dealmaking in the red‑hot obesity space, and renewed regulatory headlines around COVID‑19 vaccines. Add in a freshly declared quarterly dividend and an upcoming 2026 guidance call, and Pfizer stock is setting up for another headline-driven stretch. As of Friday’s close, Pfizer shares finished at $25.85 (up about 0.19% on the day), after trading between $25.72 and $26.04, with volume around 23 million shares. What moved Pfizer stock this
13 December 2025
·····
1 … 6 7 8 9 10

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop